Aktis Oncology Initiates Phase 1B Clinical…

Monmouth Junction, NJ. (April 15, 2013): TYRX, Inc., the leader in the commercialization of implantable medical devices intended to help reduce surgical site infections, announced today that the first implantation of its new AIGISRx R Fully Resorbable Antibacterial Envelope has taken place at the Quebec Heart and Lung Institute in Quebec City, Canada by Dr. François Philippon. TYRX announced on January 31, 2013 that it had received a license from Health Canada to market its AIGISRx R Fully Resorbable technology.